| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 50 Number 1
Volume 49 Number 6
Volume 49 Number 5
Volume 49S Number 1
Volume 49 Number 4
Volume 49 Number 3
Earlier issues
Volume  Number 

previous article next article

Research articles

ScienceAsia 48 (2022): 705-710 |doi: 10.2306/scienceasia1513-1874.2022.099

MiR-647 inhibits proliferation and improves apoptosis in cisplatin-treated non-small cell lung cancer via down-regulating IGF2 expression

Min Zhang, Hongjie Zhao, Ling Lin, Zhengang Chen*

ABSTRACT:     The purpose of this study was to identify the correlation between MiR-647 and insulin like growth factor 2(IGF2) in non-small cell lung cancer (NSCLC) and their effect on cell proliferation and apoptosis. In the study, A549 cell line was selected as NSCLC cell. The pcDNA3.1-CMV-MiR-647-EGFP and the pcDNA3.1-CMV-IGF2-mCherry were designed for the overexpression of MiR-647 and IGF2 respectively; while the pAAV-mCherry-shRNA-MiR-647 and the pAAV-EGFP-shRNA-IGF2 were respectively for MiR-647 and IGF2 knockdown in cisplatin-treated A549 cell line. Ki-67 and caspase-3 were performed to reflect cell proliferation and apoptosis in cisplatin-treated A549 cells. According to the results, MiR-647 enhanced apoptosis and cell death of cisplatin-treated NSCLC cells in vitro;, and in the cells after cisplatin treatment and MiR-647 overexpression, a significant decrease of IGF2 expression was presented. Furthermore, by plasmid transfection in cisplatin-treated A549 cells, we found that IGF2 silence and MiR-647 overexpression could synergistically promote cell apoptosis and stop NSCLC cell growth. In conclusion, MiR-647 and IGF2 have opposite effect on NSCLC cell proliferation and apoptosis; that is, MiR-647 can improve NSCLC cell apoptosis via down-regulating IGF2 expression.

Download PDF

152 Downloads 994 Views

a Department of Oncology, Tianjin Baodi Hospital, Tianjin 301800 China

* Corresponding author, E-mail: chzhengang@163.com

Received 22 Oct 2021, Accepted 17 Apr 2022